Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia

Acute Promyelocytic Leukemia Clinical Trial

— TUD-APOLLO-064  

Official title:

A Randomized Phase III Study to Compare Arsenic Trioxide (ATO) Combined to ATRA and Idarubicin Versus Standard ATRA and Anthracyclines-based Chemotherapy (AIDA Regimen) for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02688140
• Other study ID #: TUD-APOLLO-064
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: June 2016
• Est. completion date: January 2025

Study information

• Verified date: November 2023
• Source: Technische Universität Dresden
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Acute promyelocytic leukemia (APL) is a rare subtype of acute myeloid leukemia (AML) characterized by consistent clinical, morphologic, and genetic features. According to the FAB classification APL is designated as"M3 leukemia" and assigned to the WHO defined type of AML with recurrent cytogenetic abnormalities, "acute promyelocytic leukemia with t(15;17)(q22;q12), (PML/RARα) and variants". Despite the dramatic progress achieved in frontline therapy of APL with ATRA plus anthracycline-based regimens, relapses still occur in approximately 20% of patients. Moreover, these regimens are associated with significant toxicities due to severe myelosuppression frequently associated with life-threatening infections and potentially serious late effects including development of secondary MDS/AML. In a recent randomized clinical trial in low/intermediate-risk APL (WBC ≤ 10 GPt/l APL0406 trial) a combination of arsenic trioxide (ATO) and ATRA has been shown to result into better survival with significantly lower toxicity rates compared to the standard ATRA + idarubicin (AIDA) therapy. Inspired by the results of this trial the investigators intend to perform a randomized study in high-risk APL (WBC at diagnosis > 10 GPt/l) comparing standard AIDA-based treatment with ATO/ATRA combination including low-doses idarubicin during induction. The investigators propose a modified ATO/ATRA protocol with the addition of two doses of IDA (50% compared to standard AIDA induction) for induction because of the anticipated need of adding anthracyclines to control hyperleukocytosis and to achieve long-term disease control in this high-risk APL population. This is followed by 4 cycles of ATO/ATRA consolidation therapy. As in the APL0406 study for low/intermediate-risk patients the investigators expect less severe hematologic toxicity and treatment-related mortality resulting in an improved outcome for patients in the experimental arm. Furthermore, from the start of consolidation, these patients (in contrast to the standard arm) can be treated on an outpatient basis, which is also considered to be associated with an improved quality of life. The study will be conducted as a European intergroup study.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 280
• Est. completion date: January 2025
• Est. primary completion date: January 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Informed consent
• Women or men with a newly diagnosed APL by cytomorphology, confirmed by molecular analysis*
• Age = 18 and = 65 years
• ECOG performance status 0-3
• WBC at diagnosis > 10 GPt/l
• Serum total bilirubin = 3.0 mg/dl (= 51 µmol/l)
• Serum creatinine = 3.0 mg/dl (= 260 µmol/l)
• Women must fulfill at least one of the following criteria in order to be eligible for

trial inclusion:

• Post-menopausal (12 months of natural amenorrhea or 6 months of amenorrhea with Serum FSH > 40 U/ml)
• Postoperative (i.e. 6 weeks) after bilateral ovariectomy with or without hysterectomy
• Continuous and correct application of a contraception method with a Pearl Index of <1% (e.g. implants, depots, oral contraceptives, -intrauterine device - IUD)
• Sexual abstinence
• Vasectomy of the sexual partner
• The confirmation of diagnosis at genetic level (microspeckled PML nuclear distribution by PGM3 monoclonal antibody and/or PML/RARa fusion by RT-PCR or fluorescence in situ hybridization (FISH) and/or demonstration of t(15;17) at karyotyping) will be mandatory for patient eligibility. However, in order to avoid delay in treatment initiation, patients can be randomized on the basis of morphologic diagnosis only and before the results of genetic tests are available

Exclusion Criteria:

• Patients who are not eligible for chemotherapy as per discretion of the treating physician
• APL secondary to previous radio- or chemotherapy for non-APL disease
• Other active malignancy at time of study entry (exception: basal-cell carcinoma)
• Lack of diagnostic confirmation at genetic level
• Significant arrhythmias, ECG abnormalities:
• Congenital long QT syndrome;
• History or presence of significant ventricular or atrial tachyarrhythmia;
• Clinically significant resting bradycardia (<50 beats per minute)
• QTc >500msec on screening ECG for both genders (using the QTcF formula detailed on protocol)
• Right bundle branch block plus left anterior hemiblock, bifascicular block
• Other cardiac contraindications for intensive chemotherapy (L-VEF <50%)
• Uncontrolled, life-threatening infections
• Severe non controlled pulmonary or cardiac disease
• Severe hepatic or renal dysfunction
• HIV and/or active hepatitis C infection
• Pregnant or breast-feeding patients
• Allergy to trial medication or excipients in study medication
• Substance abuse; medical, psychological or social conditions that may interfere with the patients participation in the study or evaluation of the study results
• Use of other investigational drugs at the time of enrolment or within 30 days before study entry

Related Conditions & MeSH terms

• Acute Promyelocytic Leukemia
• Leukemia
• Leukemia, Promyelocytic, Acute

Intervention

Drug:
• Arsenic trioxide

• Idarubicin

• Cytarabine

• Tretinoin

• Mitoxantrone

• Mercaptopurine

• Methotrexate

Locations

Country	Name	City	State
France	French-Belgian-Swiss APL study group	Multiple Locations
Germany	AML-CG study group	Multiple Locations
Germany	AML-SG study group	Multiple Locations
Germany	OSHO study group	Multiple Locations
Germany	SAL study group	Multiple Locations
Italy	GIMEMA study group	Multiple Locations
Netherlands	HOVON study group	Multiple Locations
Spain	PETHEMA study group	Multiple Locations

Sponsors (7)

Lead Sponsor	Collaborator
Technische Universität Dresden	German Federal Ministry of Education and Research, Groupe Francophone des Myelodysplasies, Gruppo Italiano Malattie EMatologiche dell'Adulto, HOVON - Dutch Haemato-Oncology Association, Programa para el Tratamiento de Hemopatías Malignas, Teva Pharmaceuticals Europe

Countries where clinical trial is conducted

France,  Germany,  Italy,  Netherlands,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Event-free survival	events are: no achievement of haematological complete remission after induction therapy; no achievement of molecular remission after the last consolidation course; relapse; death including early death or development of secondary AML or MDS	From date of randomization until the date of first documented event, assessed up to 66 months
Secondary	Rate of hematological complete remission		up to 60 days, from date of randomization until end of induction therapy
Secondary	Rate of early death within 30 days after randomization		up to 30 days after randomization
Secondary	Rate of overall survival (OS)		at 2 years
Secondary	Rate of cumulative incidence of secondary MDS or AML		assessed up to 66 months, from date of randomization until occurance of secondary AML or MDS
Secondary	Rate of cumulative incidence of relapse (CIR)		at 2 years
Secondary	Incidence of hematological and non-hematological toxicity		assessed up to 30 months after randomization
Secondary	Rate of molecular remission after the last consolidation cycle		up to 256 days after randomization
Secondary	Assessment of acute promyelocytic leukemia/RARa transcript level reduction after induction therapy until end of study		assessed up to 30 months after randomization
Secondary	Quality of Life at the end of induction therapy until the end of study		assessed up to 30 months after randomization
Secondary	To investigate differences in the immune reconstitution between the two arms		assessed up to 30 months after randomization
Secondary	Total hospitalization days during therapy		assessed up to 30 months after randomization